Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
British Journal of Cancer|March 7, 2018
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLCMarzia Del Re, Riccardo Marconcini, Giulia Pasquini, et al.
Oncotarget|March 20, 2018
Current status and perspectives in immunotherapy for metastatic melanomaRiccardo Marconcini, Francesco Spagnolo, Luigia Stefania Stucci, et al.
Investigational New Drugs|August 26, 2016
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patientsTeresa Di Desidero, Lisa Derosa, Luca Galli, et al.
Neuroendocrinology|August 31, 2022
Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT StudyPiero Ferolla, Alfredo Berruti, Francesca Spada, et al.
Neuroendocrinology|January 21, 2016
Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological FactorsFrancesca Spada, Lorenzo Antonuzzo, Riccardo Marconcini, et al.
Frontiers in Molecular Biosciences|April 18, 2024
TGF-β mRNA levels in circulating extracellular vesicles are associated with response to anti-PD1 treatment in metastatic melanomaStefania Crucitta, Federico Cucchiara, Riccardo Marconcini, et al.
Cancers|April 13, 2023
The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN StudyMichele Del Vecchio, Vanna Chiarion Sileni, Pietro Quaglino, et al.
Clinical Case Reports|February 9, 2026
Scalp Melanoma in a Young Patient With Systemic Sarcoidosis: Multidisciplinary ApproachNicolò Mori, Adriana Ključarić, Cristian Fidanzi, et al.
Cancer Treatment Reviews|June 5, 2018
Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitorsLuigia Stefania Stucci, Stella D'Oronzo, Marco Tucci, et al.
The Oncologist|January 22, 2026
Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: Results from the MAVERIC Phase II Trial (1499 WORDS MAIN TEXT)Lorenzo Antonuzzo, Daniele Lavacchi, Francesca Spada, et al.
Pageof 5